Forte Biosciences, Inc.

NasdaqCM:FBRX Voorraadrapport

Marktkapitalisatie: US$6.1m

Forte Biosciences Beheer

Beheer criteriumcontroles 1/4

Forte Biosciences' CEO is Paul A. Wagner, appointed in Jan 2018, has a tenure of 6.83 years. total yearly compensation is $1.45M, comprised of 42.7% salary and 57.3% bonuses, including company stock and options. directly owns 5.31% of the company’s shares, worth $323.82K. The average tenure of the management team and the board of directors is 3 years and 2.3 years respectively.

Belangrijke informatie

Paul A. Wagner

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris42.7%
Dienstverband CEO6.8yrs
Eigendom CEO5.3%
Management gemiddelde ambtstermijn3yrs
Gemiddelde ambtstermijn bestuur2.3yrs

Recente managementupdates

Recent updates

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Jul 17
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Mar 14
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Large Forte Biosciences shareholder scolds company board of directors

Aug 24

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Aug 17
We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Aug 16

Forte Biosciences large shareholders make demands for company's future

Jul 07

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Dec 23
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Forte Biosciences files for $300M mixed shelf offering

May 28

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Mar 13
Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Jan 19
Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Dec 18

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Nov 25
Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences readies equity offering

Oct 28

Analyse CEO-vergoeding

Hoe is Paul A. Wagner's beloning veranderd ten opzichte van Forte Biosciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$36m

Mar 31 2024n/an/a

-US$32m

Dec 31 2023US$1mUS$620k

-US$31m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$24m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$1mUS$590k

-US$14m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$5mUS$590k

-US$22m

Sep 30 2021n/an/a

-US$23m

Jun 30 2021n/an/a

-US$20m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$777kUS$453k

-US$46m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$39m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$525kUS$350k

-US$4m

Compensatie versus markt: Paul A.'s total compensation ($USD1.45M) is above average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: Paul A.'s compensation has increased whilst the company is unprofitable.

CEO

Paul A. Wagner (54 yo)

6.8yrs

Tenure

US$1,450,175

Compensatie

Dr. Paul A. Wagner, CFA, Ph.D. has been the Senior Vice President of Corporate Strategy & Development and Chief Business Officer at CANbridge Life Sciences Ltd. since October 16, 2017. Dr. Wagner leads CAN...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Paul A. Wagner
CEO, President & Chairman6.8yrsUS$1.45m5.31%
$ 323.8k
Antony Riley
Chief Financial Officer4.7yrsUS$722.98k0.57%
$ 34.5k
Barbara Finck
Chief Medical Clinician & Directorless than a yearUS$61.73k0%
$ 0
Christopher Roenfeldt
Chief Operating Officer2.5yrsgeen gegevensgeen gegevens
Steven Ruhl
Chief Technical Officer3yrsgeen gegevensgeen gegevens

3.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: FBRX's management team is considered experienced (3 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Paul A. Wagner
CEO, President & Chairman7.8yrsUS$1.45m5.31%
$ 323.8k
Barbara Finck
Chief Medical Clinician & Director2.7yrsUS$61.73k0%
$ 0
David Gryska
Independent Director1.8yrsUS$104.30k0.41%
$ 24.8k
Richard Vincent
Independent Directorless than a yeargeen gegevensgeen gegevens
Patricia Walker
Member of Scientific Advisory Boardno dataUS$50.80kgeen gegevens
Stephen Doberstein
Member of Scientific Advisory Board & Independent Director2.5yrsUS$62.73k0%
$ 0
Steven Kornfeld
Independent Director4.4yrsUS$97.73k0.27%
$ 16.6k
Shivpreet Kapoor
Independent Directorless than a yeargeen gegevensgeen gegevens
Scott Brun
Independent Director2yrsUS$62.73k0%
$ 0
Eric Simpson
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

2.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: FBRX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.